Acadia Pharmaceuticals develops therapies for neurological disorders, focusing on conditions like Parkinson's disease, schizophrenia, and Rett syndrome. The company conducts extensive research and clinical trials to create drugs that are safe and effective, seeking approval from regulatory bodies like the FDA before bringing them to market. Acadia stands out from competitors by concentrating on areas with significant unmet medical needs and forming strategic partnerships to enhance its research and market presence. The goal of Acadia Pharmaceuticals is to improve the quality of life for patients suffering from challenging neurological diseases through effective treatments.

Biotechnology

Healthcare

Acadia Pharmaceuticals

Acadia Pharmaceuticals has hired Big Pharma veteran Thomas Andrew Garner as its new chief commercial officer (CCO).

Acadia nabs Lexicon, Bristol Myers Squibb veteran as new commercial lead

Acadia Pharmaceuticals on Tuesday said it entered into an exclusive worldwide license agreement with Saniona to develop and commercialize SAN711.

Acadia Pharmaceuticals in Exclusive License Agreement With Saniona for SAN711

US-based biopharmaceutical company Acadia Pharmaceuticals has received Health Canada marketing authorisation for Daybue (trofinetide) to treat a rare genetic neurological disorder.

Acadia gets Health Canada approval for Daybue to treat Rett Syndrome

"Week in RARE provides advocates a unique opportunity to participate in multiple events in one place to maximize their time, travel, and potential to gain benefits from their participation."

Global Genes' Annual Week In Rare Event Heading To Kansas City

Ryan & Tammy Reynolds (Photo: Business Wire)Acadia Parkinson's Fact Sheet-- The national disease awareness campaign aims to educate and drive conversation about recognizing and managing non-motor symptoms of Parkinson’s, including hallucinations and delusions-- Reynolds and his mother Tammy share their personal story about the impact of these symptoms on their familySAN DIEGO, August 14, 2024--(BUSINESS WIRE)--Ryan Reynolds, a world-renowned actor/entrepreneur and Parkinson’s disease advocate, with Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the launch of a multi-faceted disease education campaign, More to Parkinson’s®, to raise awareness among caregivers, patients and their care providers about a common, yet under-recognized aspect of Parkinson’s disease – Parkinson’s-related hallucinations and delusions.Notably, around half of the people living with Parkinson’s disease may develop hallucinations or delusions over the course of their disease, but up to 90% of people currently do not proactively tell their physicians about these symptoms.1-3 By sharing their experiences caring for Ryan’s father, James "Jim" Reynolds, who passed away nearly a decade ago, Ryan and his mother Tammy, aim to raise awareness, educate and drive conversation between people with Parkinson’s disease, their families and their doctors about how best to talk about and treat these non-motor symptoms."My father experienced hallucinations and delusions. At the time, we didn’t know any of these types of symptoms were part of his Parkinson’s disease," Reynolds explains. "Like a lot of caregivers, my mom mostly tried to carry these burdens alone. I wish I’d known Parkinson’s disease wasn’t limited to only motor symptoms. I think people and families affected by Parkinson’s can be better prepared to manage hallucinations and delusions if they’re talking early and often about this lesser-known aspect of the disease."This press release features multimedia

Ryan Reynolds Announces More To Parkinson'S(R) Campaign

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the launch of Magnolia’s Guide to Adventuring, a new, 10-part, documentary video series by award-winning TV producer, AJ Tesler, and his wife, Jenny Tesler, featuring their 13-year-old daughter, Magnolia, who lives with Rett syndrome. The series follows the Teslers as they are joined by other Rett families on adaptive adventures across the U.S., including downhill skiing, ice skating and horseback riding, to foster greater understanding and awareness of Rett syndrome while inspiring those impacted by this condition to be empowered by all the things they can do.“ We believe it’s crucial to showcase the incredible spirit of individuals living with Rett syndrome and all the things they are capable of, despite their symptoms,” said AJ Tesler, Executive Producer and Director of Magnolia’s Guide to Adventuring. “ It’s been a long journey for our family since Maggie’s Rett diagnosis, and we’ve learned how to make the most of every day by adapting adventures that we can enjoy as a family. She inspired us to make this series as a celebration of the uniqueness of each person and family affected by Rett syndrome in hopes that we can inspire all families to create their own adventures.”“ At Acadia we have had the privilege of working closely with the Rett syndrome community and have learned a lot about the lives of individuals and families living with this condition. Their journeys teach us that despite the challenges they may face, they possess remarkable abilities often unseen at first glance,” said Brendan Teehan, Executive Vice President, Chief Operating Officer, Head of Commercial

Acadia Pharmaceuticals Announces Launch Of Magnolias Guide To Adventuring: A Groundbreaking Documentary Series Aiming To Raise Disease Awareness And Redefine Perceptions Of Rett Syndrome

Acadia Pharmaceuticals Announces Launch Of Magnolia'S Guide To Adventuring: A Groundbreaking Documentary Series Aiming To Raise Disease Awareness And Redefine Perceptions Of Rett Syndrome

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it has awarded 10 academic scholarships to eligible recipients of the first Rett Sibling Scholarship. The Rett Sibling Scholarship program, sponsored by Acadia, was established in 2023 to recognize the siblings of individuals with Rett syndrome. This year’s recipients will each receive $5,000 to pursue their goals in higher education for the 2024-25 academic school year. “Families affected by Rett syndrome navigate many challenges, from medical care to balancing family, work and the daily activities of life and financial strain. Siblings often contribute by helping parents with caregiving and being a loving, supportive sibling, while also pursuing their own goals,” said Bill Keller, Acadia’s Vice President, Patient Advocacy and Industry Relations

Acadia Pharmaceuticals Is Proud To Announce The Winners Of The Inaugural Rett Sibling Scholarship

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Health Canada has accepted its New Drug Submission (NDS) for trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental disorder. Health Canada has granted Priority Review for Acadia’s submission. “Rett syndrome is a profoundly debilitating and complex neurodevelopmental disorder that presents differently across patients and can lead to an array of unpredictable symptoms,” said Pamela di Cenzo, Vice President, General Manager, Rare Disease, Canada at Acadia. “If granted marketing authorization, trofinetide will be the first option available to treat Rett syndrome in Canada.”. Health Canada grants Priority Review for drug submissions intended for the treatment, prevention, or diagnosis of serious, life-threatening, or severely debilitating illnesses or conditions for which there is substantial evidence of clinical effectiveness that the drug addresses an unmet medical need or provides a benefit/risk profile that is improved over existing therapies

Acadia Pharmaceuticals Announces Trofinetide New Drug Submission For Treatment Of Rett Syndrome Has Been Accepted For Filing And Priority Review By Health Canada

Mutual of America Capital Management LLC invests $2.21 million in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD).

Mutual of America Capital Management LLC Invests $2.21 Million in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Develops therapies for neurological disorders

Acadia Pharmaceuticals

Develops therapies for neurological disorders

Acadia Pharmaceuticals

Develops therapies for neurological disorders

About

Simplify's Take

What believers are saying

What critics are saying

What makes Acadia Pharmaceuticals unique

Benefits

Recently Posted Jobs

Acadia Pharmaceuticals is Hiring for 0 Jobs on Simplify!